Amarin Sinks After Vascepa Patent Trial Judges Are Revealed
Shares of Amarin (AMRN) moved lower after the judges were posted for the company's Federal Circuit appeal of the Vascepa patent invalidation versus generics.
The appeal judges will be Timothy Dyk, Jimmie Reyna and Todd Hughes. In a research note yesterday, Piper Jaffray analyst Yasmeen Rahimi said Dyk is likely to have a favorable perspective on intellectual property appeals while Reyna is more likely to favor generics and Hughes is likely to favor patent protection rights.
Shares of Amarin are down 12%, or 85c, to $6.41 in premarket trading.
Disclosure: None.
How did you like this article? Let us know so we can better customize your reading experience.
It is very interesting that judges have such a track record that they have a large effect on share pricing. I am quite impressed.